Deaths and disability from natalizumab are no longer tolerable: Yes

Abstract

Get full access to this article

View all access options for this article.

References

Tremlett

Yinshan Zhao Devonshire

. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008; 14: 314–324.

Tremlett

Paty

Devonshire

. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66: 172–177.

Pucci

Giuliani

Solari

Simi

Minozzi

Di Pietrantonj

, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011; 10: CD007621.

Fox

Rudick

. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78: 436–437.

Goodin

Cohen

O’Connor

Kappos

Stevens

. Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71: 766–773.

Keegan

. Natalizumab for multiple sclerosis: a complicated treatment. Lancet Neurol 2011; 10: 677–678.

Rammohan

Ortega

Delgado

Tornes

. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 77: 1930; discussion 1930–1931.

Tan

McArthur

Clifford

Major

Nath

. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77: 1061–1067.

Rispens

Vennegoor

Wolbink

Polman

Killestein

. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. 2012; 18(6): 899–901.